Skip to main content

PGD conditions

This table shows all PGD conditions currently approved and awaiting consideration by the HFEA.

Please note that we are updating this database, and some approved conditions may not be displayed. If you are unsure if a condition has been approved or not, please contact pgd@hfea.gov.uk.

Condition name Status OMIM number Documents
Lymphatic malformation 1, (LMPHM1) (Milroy Syndrome) approved 153100
Lymphatic malformation 3, (LMPHM3) approved 613480
Lymphatic malformation 4, (LMPHM4) approved 615907
Lymphatic malformation 6, (LMPHM6) approved 616843
Lymphatic malformation 7, (LMPHM7) approved 617300
Lymphoproliferative Syndrome, X-linked,1 (XLR) approved 308240
Mabry Syndrome (Hyperphosphatasia mental retardation syndrome-HPMRS), Type 1 approved 239300
Malignant Infantile Osteopetrosis approved 259700
Maple Syrup Urine Disorder (MSUD) approved 248600
Marfan Syndrome (MFS) approved 154700
Meckel-Gruber Syndrome Types 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 approved 249000, 603194, 607361, 611134, 611561, 612284, 267010, 613885, 614209, 614175 and 615397
Medium-Chain Acyl-CoA Dehydrogenase Deficiency approved 201450
Medullary Cystic Kidney Disease 2 (MCKD2) (also known as Autosomal Dominant Tubulointerstitial Kidney Disease due to Uromodulin Mutations (ADTKD-UMOD) approved 603860
MEGABLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE (DHFR) DEFICIENCY awaiting approval 613839
MEGDEL syndrome (3-Methylglutaconic Aciduria with Deafness, Encephalopathy, and Leigh-Like Syndrome) approved 614739
Melanoma Pancreatic Cancer Syndrome approved 606719
Melanoma, cutaneous malignant, susceptibility to, 10 (CMM10) approved 615848
Melanoma, cutaneous malignant, susceptibility to, 2 (CMM2) approved 155601
Melanoma, cutaneous malignant, susceptibility to, 3 (CMM3) approved 609048
Melanoma-Astrocytoma Syndrome approved 155755